The polymorphic drug substances of the European pharmacopoeia. Part 9. Physicochemical properties and crystal structure of acetazolamide crystal forms.

The crystal structure of acetazolamide modification I (mod. I) was determined, and its differences compared with the already known crystal structure of the triclinic modification II (mod. II) are discussed. The monoclinic mod. I crystallizes in space group P2(1)/n with four molecules in the unit cell: a = 4.7674, b = 21.956, and c = 8.186 A, beta = 104.23 degrees. In both modifications, the molecules form hydrogen-bonded centrosymmetric dimers. The two modifications differ distinctly in the spatial arrangement of these pairs and in the hydrogen bonds formed between them. The thermodynamic relationship between the two modifications is demonstrated by a semischematic energy/temperature diagram, based on the results of thermal analysis and solubility experiments. Mod. II is the thermodynamically stable modification at 20 degrees C and enantiotropically related to mod. I. The thermodynamic transition point lies between 120 and 148 degrees C. The solid-state properties of acetazolamide are mainly directed by the strong intermolecular hydrogen bond forces. Thus, the metastable mod. I exhibits a higher density than mod. II and a very high kinetic stability at 20 degrees C. Both modifications can be crystallized from water and the solubility differences are very small, so, in addition to mod. II, the metastable but extremely resistant mod. I is suggested to be suitable for use in solid pharmaceutical formulations.

[1]  J. Bernstein,et al.  Conformational polymorphism VI: the crystal and molecular structures of form II, form III, and form V of 4-amino-N-2-pyridinylbenzenesulfonamide (sulfapyridine). , 1985, Journal of pharmaceutical sciences.

[2]  C. Markopoulou,et al.  The x-ray characterization of 12 diuretics , 1992 .

[3]  A. Hagler,et al.  Conformational polymorphism. The influence of crystal structure on molecular conformation , 1978 .

[4]  J. Bernstein,et al.  Graph-set analysis of hydrogen-bond patterns in organic crystals. , 1990, Acta crystallographica. Section B, Structural science.

[5]  S. K. Sikka,et al.  High pressure phase transitions in organic solids I:α → β transition in resorcinol , 1985 .

[6]  A. Burger,et al.  On the polymorphism of pharmaceuticals and other molecular crystals. II , 1979 .

[7]  J. Parasrampuria,et al.  Development of oral liquid dosage forms of acetazolamide. , 1990, Journal of pharmaceutical sciences.

[8]  Liat Shimoni,et al.  Muster aus H‐Brücken: ihre Funktionalität und ihre graphentheoretische Analyse in Kristallen , 1995 .

[9]  U. Griesser,et al.  Physical stability, hygroscopicity and solubility of succinylsulfathiazole crystal forms. The polymorphic drug substances of the European pharmacopoeia. VII , 1991 .

[10]  M. Kuhnert-Brandstätter,et al.  Polymorphie und Mischkristallbildung bei Sulfonamiden und verwandten Verbindungen , 1969 .

[11]  A. Burger,et al.  On the polymorphism of pharmaceuticals and other molecular crystals. I , 1979 .

[12]  G. W. Anderson,et al.  1,3,4-Thiadiazole- and Thiadiazolinesulfonamides as Carbonic Anhydrase Inhibitors. Synthesis and Structural Studies , 1956 .

[13]  Y. Mnyukh Molecular Mechanism of Polymorphic Transitions , 1971 .

[14]  Y. Mnyukh Polymorphic transitions in crystals: Nucleation , 1976 .

[15]  A. Chow,et al.  NON – LINEAR VAN'T HOFF SOLUBILITY TEMPERATURE PLOTS AND THEIR PHARMACEUTICAL INTERPRETATION , 1984 .

[16]  J. Robertson,et al.  A new form of resorcinol. I. Structure determination by X-rays , 1938, Proceedings of the Royal Society of London. Series A. Mathematical and Physical Sciences.

[17]  Heinz W. Siesler,et al.  Theoretical derivation and practical application of energy/temperature diagrams as an instrument in preformulation studies of polymorphic drug substances. , 1996 .

[18]  M. Mathew,et al.  Crystal and molecular structure of acetazolamide (5-acetamido-1,3,4-thiadiazole-2-sulphonamide), a potent inhibitor of carbonic anhydrase , 1974 .

[19]  Wilbur H. Miller,et al.  Heterocyclic Sulfonamides as Carbonic Anhydrase Inhibitors1 , 1950 .